The U.S. Food and Drug Administration (FDA) has cleared an application from Emerald Health Pharmaceuticals that paves the way to…
Articles by Marisa Wexler, MS
About a third of people diagnosed with scleroderma in the U.S. were prescribed immunosuppressive therapies in the first…
Treatment with Letairis (ambrisentan) failed to significantly reduce pulmonary blood pressure at rest and during exercise compared with…
The first person has been enrolled in a clinical trial evaluating the investigational therapy bermekimab in adults with scleroderma,…
A modified version of the inflammatory protein TRAIL might be able to reverse fibrosis in scleroderma and related conditions, a…
The Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has recommended — via a 10-7…
Older age, active digital ulcers, lung tissue scarring, muscle weakness, and increased levels of C-reactive protein (CRP) are predictive factors…